Paradoxical association between dyspepsia and autoimmune chronic atrophic gastritis: Insights into mechanisms, pathophysiology, and treatment options.
Autoimmune gastritis
Chronic autoimmune atrophic gastritis
Dyspepsia
Dyspeptic symptoms
Gastro-intestinal symptoms
Treatment
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 Jun 2023
21 Jun 2023
Historique:
received:
21
03
2023
revised:
23
04
2023
accepted:
06
05
2023
medline:
5
7
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
ppublish
Résumé
Autoimmune gastritis (AIG) is a progressive, chronic, immune-mediated inflammatory disease characterized by the destruction of gastric parietal cells leading to hypo/anacidity and loss of intrinsic factor. Gastrointestinal symptoms such as dyspepsia and early satiety are very common, being second in terms of frequency only to anemia, which is the most typical feature of AIG. To address both well-established and more innovative information and knowledge about this challenging disorder. An extensive bibliographical search was performed in PubMed to identify guidelines and primary literature (retrospective and prospective studies, systematic reviews, case series) published in the last 10 years. A total of 125 records were reviewed and 80 were defined as fulfilling the criteria. AIG can cause a range of clinical manifestations, including dyspepsia. The pathophysiology of dyspepsia in AIG is complex and involves changes in acid secretion, gastric motility, hormone signaling, and gut microbiota, among other factors. Managing dyspeptic symptoms of AIG is challenging and there are no specific therapies targeting dyspepsia in AIG. While proton pump inhibitors are commonly used to treat dyspepsia and gastroesophageal reflux disease, they may not be appropriate for AIG. Prokinetic agents, antidepressant drugs, and non-pharmacological treatments may be of help, even if not adequately evidence-based supported. A multidisciplinary approach for the management of dyspepsia in AIG is recommended, and further research is needed to develop and validate more effective therapies for dyspepsia.
Sections du résumé
BACKGROUND
BACKGROUND
Autoimmune gastritis (AIG) is a progressive, chronic, immune-mediated inflammatory disease characterized by the destruction of gastric parietal cells leading to hypo/anacidity and loss of intrinsic factor. Gastrointestinal symptoms such as dyspepsia and early satiety are very common, being second in terms of frequency only to anemia, which is the most typical feature of AIG.
AIM
OBJECTIVE
To address both well-established and more innovative information and knowledge about this challenging disorder.
METHODS
METHODS
An extensive bibliographical search was performed in PubMed to identify guidelines and primary literature (retrospective and prospective studies, systematic reviews, case series) published in the last 10 years.
RESULTS
RESULTS
A total of 125 records were reviewed and 80 were defined as fulfilling the criteria.
CONCLUSION
CONCLUSIONS
AIG can cause a range of clinical manifestations, including dyspepsia. The pathophysiology of dyspepsia in AIG is complex and involves changes in acid secretion, gastric motility, hormone signaling, and gut microbiota, among other factors. Managing dyspeptic symptoms of AIG is challenging and there are no specific therapies targeting dyspepsia in AIG. While proton pump inhibitors are commonly used to treat dyspepsia and gastroesophageal reflux disease, they may not be appropriate for AIG. Prokinetic agents, antidepressant drugs, and non-pharmacological treatments may be of help, even if not adequately evidence-based supported. A multidisciplinary approach for the management of dyspepsia in AIG is recommended, and further research is needed to develop and validate more effective therapies for dyspepsia.
Identifiants
pubmed: 37398891
doi: 10.3748/wjg.v29.i23.3733
pmc: PMC10311608
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3733-3747Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors declare no conflict of interests for this article.
Références
J Endocrinol Invest. 2018 May;41(5):523-529
pubmed: 28929353
J Gastrointest Surg. 2008 Sep;12(9):1491-6
pubmed: 18612705
Cochrane Database Syst Rev. 2014 Dec 02;(12):CD010623
pubmed: 25464111
Scand J Gastroenterol. 2017 Feb;52(2):230-237
pubmed: 27806647
Gut. 2005 Apr;54(4):449-54
pubmed: 15753524
J Gastrointestin Liver Dis. 2021 Mar 13;30(1):30-36
pubmed: 33723550
Neurogastroenterol Motil. 2015 Feb;27(2):160-74
pubmed: 25469569
Gastroenterology. 2001 Jun;120(7):1599-606
pubmed: 11375942
Neurogastroenterol Motil. 2016 May;28(5):758-64
pubmed: 26813266
J Neurogastroenterol Motil. 2014 Apr 30;20(2):265-70
pubmed: 24840380
Aliment Pharmacol Ther. 2003 Jul 15;18(2):245-52
pubmed: 12869086
Acta Biomed. 2022 Jul 01;93(3):e2022184
pubmed: 35775759
Gut. 2022 Sep;71(9):1697-1723
pubmed: 35798375
PLoS One. 2014 Jul 08;9(7):e101852
pubmed: 25003598
Gut. 2023 Jan;72(1):30-38
pubmed: 35772926
World J Gastroenterol. 2018 Jun 14;24(22):2373-2380
pubmed: 29904244
Neurogastroenterol Motil. 2018 Jan;30(1):
pubmed: 28851005
Ann Palliat Med. 2022 Oct;11(10):3147-3159
pubmed: 36096741
Clin Gastroenterol Hepatol. 2012 Jul;10(7):812-4
pubmed: 22387252
J Bone Miner Res. 1992 May;7(5):573-9
pubmed: 1615763
Curr Gastroenterol Rep. 2016 Mar;18(3):14
pubmed: 26908282
Gastroenterology. 2021 Oct;161(4):1325-1332.e7
pubmed: 34454714
Am J Med Sci. 2018 May;355(5):428-433
pubmed: 29753372
Dis Esophagus. 2016 Jan;29(1):3-9
pubmed: 25212408
Dig Dis Sci. 2016 Jun;61(6):1597-602
pubmed: 26725066
Gastroenterology. 2021 May;160(6):2006-2017
pubmed: 33548234
Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):529-41
pubmed: 23774773
Aliment Pharmacol Ther. 2020 Mar;51(6):582-602
pubmed: 32056247
Autoimmun Rev. 2019 Mar;18(3):215-222
pubmed: 30639639
Am J Gastroenterol. 2017 Jul;112(7):988-1013
pubmed: 28631728
Gastrointest Endosc. 2010 Jun;71(7):1150-8
pubmed: 20381801
Dig Liver Dis. 2019 Dec;51(12):1621-1632
pubmed: 31635944
Therap Adv Gastroenterol. 2011 Sep;4(5):295-300
pubmed: 21922028
Arch Pathol Lab Med. 2019 Nov;143(11):1327-1331
pubmed: 31661309
Dig Dis Sci. 2021 Oct;66(10):3322-3329
pubmed: 33098024
Neurogastroenterol Motil. 2021 Aug;33(8):e14064
pubmed: 33314491
Am J Physiol Gastrointest Liver Physiol. 2021 Aug 1;321(2):G133-G138
pubmed: 34160292
Nat Rev Dis Primers. 2020 Jul 9;6(1):56
pubmed: 32647173
Alcohol Clin Exp Res. 2011 Mar;35(3):516-22
pubmed: 21143248
Neurogastroenterol Motil. 2015 Apr;27(4):524-31
pubmed: 25712043
Dig Dis Sci. 2021 May;66(5):1442-1445
pubmed: 32974808
Dig Liver Dis. 2021 Dec;53(12):1580-1587
pubmed: 34116969
World J Gastroenterol. 2009 Jun 21;15(23):2834-8
pubmed: 19533804
Medicine (Baltimore). 2017 Jan;96(1):e5784
pubmed: 28072728
Curr Gastroenterol Rep. 2020 Jun 15;22(8):38
pubmed: 32542467
BMC Gastroenterol. 2018 Nov 8;18(1):172
pubmed: 30409113
World J Gastroenterol. 2018 Mar 28;24(12):1343-1352
pubmed: 29599609
Helicobacter. 2007 Feb;12(1):23-30
pubmed: 17241297
Aliment Pharmacol Ther. 2019 May;49(9):1134-1172
pubmed: 30924176
Acta Biomed. 2018 Dec 17;89(8-S):88-92
pubmed: 30561424
Dig Dis. 2023;41(2):198-205
pubmed: 36423587
Gut. 2006 Oct;55(10):1398-402
pubmed: 16556669
Front Immunol. 2022 Oct 27;13:1070250
pubmed: 36389672
Digestion. 2018;97(4):333-339
pubmed: 29587295
Helicobacter. 2023 Apr;28(2):e12952
pubmed: 36897573
J Gastroenterol Hepatol. 2021 Aug;36(8):2083-2090
pubmed: 33403702
Gut. 2023 May;72(5):1019-1020
pubmed: 35697421
Nutrients. 2010 Mar;2(3):299-316
pubmed: 22254022
PLoS One. 2015 Apr 01;10(4):e0120397
pubmed: 25831092
PLoS Pathog. 2017 Nov 2;13(11):e1006653
pubmed: 29095917
Gastrointest Endosc. 2021 Jul;94(1):35-44
pubmed: 33373646
J Nucl Med Technol. 2008 Mar;36(1):44-54
pubmed: 18287197
Scand J Gastroenterol. 2015;50(11):1397-403
pubmed: 26059834
Gut. 2005 Oct;54(10):1370-6
pubmed: 15972301
J Gastroenterol. 2022 Feb;57(2):47-61
pubmed: 35061057
Nat Rev Dis Primers. 2020 Jul 9;6(1):57
pubmed: 32647157
Gut. 2018 Jul;67(7):1351-1362
pubmed: 29437910
Therap Adv Gastroenterol. 2021 Aug 31;14:17562848211038771
pubmed: 34484423
Scand J Gastroenterol. 2019 Jan;54(1):35-40
pubmed: 30638085
Gut. 2007 May;56(5):631-6
pubmed: 17142647
Neurogastroenterol Motil. 2023 Feb;35(2):e14529
pubmed: 36594414
Clin Gastroenterol Hepatol. 2022 May;20(5):984-994.e1
pubmed: 35123084
Am J Surg Pathol. 1996 Oct;20(10):1161-81
pubmed: 8827022
Neurogastroenterol Motil. 2016 Feb;28(2):274-80
pubmed: 26568317
Alcohol Clin Exp Res. 1996 Sep;20(6):967-72
pubmed: 8892513
Surg Endosc. 2021 Apr;35(4):1755-1764
pubmed: 32328824
Aliment Pharmacol Ther. 2023 Apr;57(8):851-860
pubmed: 36859629
Am J Gastroenterol. 2022 Aug 1;117(8):1197-1220
pubmed: 35926490
Aliment Pharmacol Ther. 2015 Feb;41(4):360-7
pubmed: 25523288
Am J Gastroenterol. 2000 Jun;95(6):1448-55
pubmed: 10894577